Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 523 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 523 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $27.20, for a total transaction of $14,225.60. Following the transaction, the executive vice president now directly owns 283,919 shares of the company’s stock, valued at $7,722,596.80. The trade was a 0.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

BioLife Solutions Stock Up 1.1 %

Shares of BLFS stock opened at $27.47 on Friday. BioLife Solutions, Inc. has a 1 year low of $11.91 and a 1 year high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The business’s fifty day moving average is $24.19 and its 200-day moving average is $23.19. The stock has a market cap of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BLFS. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities increased their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, HC Wainwright cut their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at about $28,000. 1620 Investment Advisors Inc. bought a new stake in shares of BioLife Solutions in the 2nd quarter worth approximately $35,000. Quest Partners LLC acquired a new stake in BioLife Solutions during the third quarter valued at approximately $57,000. GAMMA Investing LLC boosted its holdings in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in BioLife Solutions during the second quarter worth approximately $122,000. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.